-
2
-
-
79953074627
-
Prevalence of dermatological disorders in Japan: A nationwide, cross-sectional, seasonal, multicenter, hospital-based study
-
Furue M, Yamazaki S, Jimbow K, et al,. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol 2011; 38: 310-320.
-
(2011)
J Dermatol
, vol.38
, pp. 310-320
-
-
Furue, M.1
Yamazaki, S.2
Jimbow, K.3
-
3
-
-
84877774022
-
The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men
-
Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M,. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE 2013; 8: e63619.
-
(2013)
PLoS ONE
, vol.8
, pp. e63619
-
-
Hägg, D.1
Eriksson, M.2
Sundström, A.3
Schmitt-Egenolf, M.4
-
4
-
-
84883557886
-
Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic
-
Na SJ, Jo SJ, Youn JI,. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol 2013; 40: 731-735.
-
(2013)
J Dermatol
, vol.40
, pp. 731-735
-
-
Na, S.J.1
Jo, S.J.2
Youn, J.I.3
-
5
-
-
84920747894
-
Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms
-
Baurecht H, Hotze M, Brand S, et al,. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet 2015; 96: 104-120.
-
(2015)
Am J Hum Genet
, vol.96
, pp. 104-120
-
-
Baurecht, H.1
Hotze, M.2
Brand, S.3
-
6
-
-
84891372710
-
A large-scale screen for coding variants predisposing to psoriasis
-
Tang H, Jin X, Li Y, et al,. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 2014; 46: 45-50.
-
(2014)
Nat Genet
, vol.46
, pp. 45-50
-
-
Tang, H.1
Jin, X.2
Li, Y.3
-
7
-
-
84872497387
-
Transcriptional regulatory network for psoriasis
-
Lu X, Du J, Liang J, et al,. Transcriptional regulatory network for psoriasis. J Dermatol 2013; 40: 48-53.
-
(2013)
J Dermatol
, vol.40
, pp. 48-53
-
-
Lu, X.1
Du, J.2
Liang, J.3
-
8
-
-
84962403206
-
CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort
-
Feng C, Wang T, Li SJ, et al,. CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort. J Dermatol 2015; doi: 10.1111/1346-8138.13039.
-
(2015)
J Dermatol
-
-
Feng, C.1
Wang, T.2
Li, S.J.3
-
9
-
-
84905645216
-
HLA-C 12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese
-
Mabuchi T, Ota T, Manabe Y, et al,. HLA-C 12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol 2014; 41: 697-704.
-
(2014)
J Dermatol
, vol.41
, pp. 697-704
-
-
Mabuchi, T.1
Ota, T.2
Manabe, Y.3
-
10
-
-
84883560723
-
Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis
-
Kanazawa N, Nakamura T, Mikita N, Furukawa F,. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol 2013; 40: 749-751.
-
(2013)
J Dermatol
, vol.40
, pp. 749-751
-
-
Kanazawa, N.1
Nakamura, T.2
Mikita, N.3
Furukawa, F.4
-
11
-
-
84937597306
-
Identification of Two Loci Associated with Generalized Pustular Psoriasis
-
Zhang Z, Ma Y, Zhang Z, et al,. Identification of Two Loci Associated with Generalized Pustular Psoriasis. J Invest Dermatol 2015; 135: 2132-2134.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 2132-2134
-
-
Zhang, Z.1
Ma, Y.2
Zhang, Z.3
-
12
-
-
84926224828
-
IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis
-
Hussain S, Berki DM, Choon SE, et al,. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015; 135: 1067-1070.
-
(2015)
J Allergy Clin Immunol
, vol.135
, pp. 1067-1070
-
-
Hussain, S.1
Berki, D.M.2
Choon, S.E.3
-
13
-
-
84884283813
-
Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis
-
Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH,. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-2346.
-
(2013)
J Invest Dermatol
, vol.133
, pp. 2340-2346
-
-
Samarasekera, E.J.1
Neilson, J.M.2
Warren, R.B.3
Parnham, J.4
Smith, C.H.5
-
14
-
-
84928419406
-
Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures
-
Koch M, Baurecht H, Ried JS, et al,. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol 2015; 135: 1283-1293.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 1283-1293
-
-
Koch, M.1
Baurecht, H.2
Ried, J.S.3
-
15
-
-
84939432672
-
Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink
-
Parisi R, Rutter MK, Lunt M, et al,. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. J Invest Dermatol 2015; 135: 2189-2197.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 2189-2197
-
-
Parisi, R.1
Rutter, M.K.2
Lunt, M.3
-
16
-
-
84886953964
-
Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease
-
Torres T, Sales R, Vasconcelos C, et al,. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013; 40: 923-926.
-
(2013)
J Dermatol
, vol.40
, pp. 923-926
-
-
Torres, T.1
Sales, R.2
Vasconcelos, C.3
-
17
-
-
39149111552
-
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease
-
Wolf N, Quaranta M, Prescott NJ, et al,. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008; 45: 114-116.
-
(2008)
J Med Genet
, vol.45
, pp. 114-116
-
-
Wolf, N.1
Quaranta, M.2
Prescott, N.J.3
-
18
-
-
84877750779
-
Case of Vogt-Koyanagi-Harada disease with psoriasis vulgaris
-
Uchiyama M, Mitsuhashi Y, Okubo Y, Goto H, Tsuboi R,. Case of Vogt-Koyanagi-Harada disease with psoriasis vulgaris. J Dermatol 2013; 40: 355-356.
-
(2013)
J Dermatol
, vol.40
, pp. 355-356
-
-
Uchiyama, M.1
Mitsuhashi, Y.2
Okubo, Y.3
Goto, H.4
Tsuboi, R.5
-
19
-
-
84886951791
-
Psoriasis vulgaris associated with Vogt-Koyanagi-Harada syndrome
-
Takahashi H, Tsuji H, Iizuka H,. Psoriasis vulgaris associated with Vogt-Koyanagi-Harada syndrome. J Dermatol 2013; 40: 933-934.
-
(2013)
J Dermatol
, vol.40
, pp. 933-934
-
-
Takahashi, H.1
Tsuji, H.2
Iizuka, H.3
-
20
-
-
84878563091
-
Simultaneous diagnosis of Kaposi's sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient
-
Sorce M, Bongiorno MR,. Simultaneous diagnosis of Kaposi's sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient. J Dermatol 2013; 40: 479-480.
-
(2013)
J Dermatol
, vol.40
, pp. 479-480
-
-
Sorce, M.1
Bongiorno, M.R.2
-
21
-
-
84903814334
-
Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab
-
Kajihara I, Makino K, Ichihara A, et al,. Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab. J Dermatol 2014; 41: 670-671.
-
(2014)
J Dermatol
, vol.41
, pp. 670-671
-
-
Kajihara, I.1
Makino, K.2
Ichihara, A.3
-
22
-
-
84900033354
-
Three cases of psoriasis vulgaris associated with myasthenia gravis
-
Takahashi H, Tsuji H, Iizuk H,. Three cases of psoriasis vulgaris associated with myasthenia gravis. J Dermatol 2014; 41: 462-463.
-
(2014)
J Dermatol
, vol.41
, pp. 462-463
-
-
Takahashi, H.1
Tsuji, H.2
Iizuk, H.3
-
23
-
-
84914154389
-
Case of anti-laminin gamma-1 pemphigoid with antibody against C-terminal domain of BP180 in a patient with psoriasis vulgaris
-
Ansai S, Hashizume S, Kawana S, et al,. Case of anti-laminin gamma-1 pemphigoid with antibody against C-terminal domain of BP180 in a patient with psoriasis vulgaris. J Dermatol 2014; 41: 1031-1033.
-
(2014)
J Dermatol
, vol.41
, pp. 1031-1033
-
-
Ansai, S.1
Hashizume, S.2
Kawana, S.3
-
24
-
-
84926431257
-
Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: Successful disease control with cyclosporin
-
Imanishi A, Tateishi C, Imanishi H, et al,. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin. J Dermatol 2015; 42: 394-397.
-
(2015)
J Dermatol
, vol.42
, pp. 394-397
-
-
Imanishi, A.1
Tateishi, C.2
Imanishi, H.3
-
25
-
-
84872501716
-
Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept
-
Nin M, Tokunaga D, Ishii N, et al,. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 2013; 40: 55-56.
-
(2013)
J Dermatol
, vol.40
, pp. 55-56
-
-
Nin, M.1
Tokunaga, D.2
Ishii, N.3
-
26
-
-
84878604671
-
Profile of patients with psoriasis associated with hepatitis C virus infection
-
Imafuku S, Nakayama J,. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol 2013; 40: 428-433.
-
(2013)
J Dermatol
, vol.40
, pp. 428-433
-
-
Imafuku, S.1
Nakayama, J.2
-
27
-
-
84885187774
-
Possible association of hepatitis C virus infection with late-onset psoriasis: A hospital-based observational study
-
Imafuku S, Naito R, Nakayama J,. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol 2013; 40: 813-818.
-
(2013)
J Dermatol
, vol.40
, pp. 813-818
-
-
Imafuku, S.1
Naito, R.2
Nakayama, J.3
-
28
-
-
84865625777
-
Alcohol consumption and psoriatic risk: A meta-analysis of case-control studies
-
Zhu KJ, Zhu CY, Fan YM,. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol 2012; 39: 770-773.
-
(2012)
J Dermatol
, vol.39
, pp. 770-773
-
-
Zhu, K.J.1
Zhu, C.Y.2
Fan, Y.M.3
-
29
-
-
84878600624
-
Alcohol consumption: Is it really a risk factor for psoriasis?
-
Brenaut E, Barnetche T, Misery L,. Alcohol consumption: is it really a risk factor for psoriasis? J Dermatol 2013; 40: 508.
-
(2013)
J Dermatol
, vol.40
, pp. 508
-
-
Brenaut, E.1
Barnetche, T.2
Misery, L.3
-
30
-
-
84878619334
-
Alcohol consumption: Is it really a risk factor for psoriasis?: Reply to Emilie Brenaut's letter
-
Zhu KJ, Zhu CY,. Alcohol consumption: is it really a risk factor for psoriasis?: Reply to Emilie Brenaut's letter. J Dermatol 2013; 40: 509.
-
(2013)
J Dermatol
, vol.40
, pp. 509
-
-
Zhu, K.J.1
Zhu, C.Y.2
-
31
-
-
84880308810
-
Alcohol consumption and psoriasis: A systematic literature review
-
Brenaut E, Horreau C, Pouplard C, et al,. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27 (Suppl 3): 30-35.
-
(2013)
J Eur Acad Dermatol Venereol
, vol.27
, pp. 30-35
-
-
Brenaut, E.1
Horreau, C.2
Pouplard, C.3
-
32
-
-
84857985148
-
The cellular and signaling networks linking the immune system and metabolism in disease
-
Osborn O, Olefsky JM,. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374.
-
(2012)
Nat Med
, vol.18
, pp. 363-374
-
-
Osborn, O.1
Olefsky, J.M.2
-
33
-
-
84955166784
-
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells
-
Shibata S, Tada Y, Hau CS, et al,. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun 2015; 6: 7687.
-
(2015)
Nat Commun
, vol.6
, pp. 7687
-
-
Shibata, S.1
Tada, Y.2
Hau, C.S.3
-
34
-
-
79952434300
-
Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: Induction of elevated serum adiponectin levels following therapy
-
Shibata S, Tada Y, Hau C, et al,. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011; 164: 667-670.
-
(2011)
Br J Dermatol
, vol.164
, pp. 667-670
-
-
Shibata, S.1
Tada, Y.2
Hau, C.3
-
35
-
-
84878585734
-
Serum level of adiponectin increases and those of leptin and resistin decrease following the treatment of psoriasis
-
Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Serum level of adiponectin increases and those of leptin and resistin decrease following the treatment of psoriasis. J Dermatol 2013; 40: 475-476.
-
(2013)
J Dermatol
, vol.40
, pp. 475-476
-
-
Takahashi, H.1
Tsuji, H.2
Ishida-Yamamoto, A.3
Iizuka, H.4
-
36
-
-
84878560584
-
Adiponectin levels in patients with psoriasis: A meta-analysis
-
Zhu KJ, Shi G, Zhang C, et al,. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol 2013; 40: 438-442.
-
(2013)
J Dermatol
, vol.40
, pp. 438-442
-
-
Zhu, K.J.1
Shi, G.2
Zhang, C.3
-
37
-
-
84936891385
-
IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases
-
Teng MW, Bowman EP, McElwee JJ, et al,. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-729.
-
(2015)
Nat Med
, vol.21
, pp. 719-729
-
-
Teng, M.W.1
Bowman, E.P.2
McElwee, J.J.3
-
38
-
-
84937642086
-
IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies
-
Blauvelt A, Lebwohl MG, Bissonnette R,. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol 2015; 135: 1946-1953.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 1946-1953
-
-
Blauvelt, A.1
Lebwohl, M.G.2
Bissonnette, R.3
-
39
-
-
34948862264
-
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
-
Lande R, Gregorio J, Facchinetti V, et al,. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
-
(2007)
Nature
, vol.449
, pp. 564-569
-
-
Lande, R.1
Gregorio, J.2
Facchinetti, V.3
-
40
-
-
22344438901
-
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production
-
Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
-
(2005)
J Exp Med
, vol.202
, pp. 135-143
-
-
Nestle, F.O.1
Conrad, C.2
Tun-Kyi, A.3
-
41
-
-
84856100861
-
Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands
-
Morizane S, Yamasaki K, Mühleisen B, et al,. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 2012; 132: 135-143.
-
(2012)
J Invest Dermatol
, vol.132
, pp. 135-143
-
-
Morizane, S.1
Yamasaki, K.2
Mühleisen, B.3
-
43
-
-
0037449737
-
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
-
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
-
(2003)
J Biol Chem
, vol.278
, pp. 1910-1914
-
-
Aggarwal, S.1
Ghilardi, N.2
Xie, M.H.3
De Sauvage, F.J.4
Gurney, A.L.5
-
44
-
-
34249026701
-
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17
-
LeibundGut-Landmann S, Gross O, Robinson MJ, et al,. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-638.
-
(2007)
Nat Immunol
, vol.8
, pp. 630-638
-
-
LeibundGut-Landmann, S.1
Gross, O.2
Robinson, M.J.3
-
45
-
-
84866551186
-
Microbial-induced Th17: Superhero or supervillain?
-
McGeachy MJ, McSorley SJ,. Microbial-induced Th17: superhero or supervillain? J Immunol 2012; 189: 3285-3291.
-
(2012)
J Immunol
, vol.189
, pp. 3285-3291
-
-
McGeachy, M.J.1
McSorley, S.J.2
-
46
-
-
80052661515
-
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis
-
Laggner U, Di Meglio P, Perera GK, et al,. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 2011; 187: 2783-2793.
-
(2011)
J Immunol
, vol.187
, pp. 2783-2793
-
-
Laggner, U.1
Di Meglio, P.2
Perera, G.K.3
-
47
-
-
84937945349
-
Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses
-
Ramírez-Valle F, Gray EE, Cyster JG,. Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc Natl Acad Sci USA 2015; 112: 8046-8051.
-
(2015)
Proc Natl Acad Sci USA
, vol.112
, pp. 8046-8051
-
-
Ramírez-Valle, F.1
Gray, E.E.2
Cyster, J.G.3
-
48
-
-
84930572248
-
Dermal γδ T cells - What have we learned?
-
O'Brien RL, Born WK,. Dermal γδ T cells-What have we learned? Cell Immunol 2015; 296: 62-69.
-
(2015)
Cell Immunol
, vol.296
, pp. 62-69
-
-
O'Brien, R.L.1
Born, W.K.2
-
49
-
-
84906215927
-
A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells
-
Ward NL, Umetsu DT,. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Invest Dermatol 2014; 134: 2305-2307.
-
(2014)
J Invest Dermatol
, vol.134
, pp. 2305-2307
-
-
Ward, N.L.1
Umetsu, D.T.2
-
50
-
-
84909959109
-
The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells
-
Teunissen MB, Yeremenko NG, Baeten DL, et al,. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 2014; 134: 2898-2907.
-
(2014)
J Invest Dermatol
, vol.134
, pp. 2898-2907
-
-
Teunissen, M.B.1
Yeremenko, N.G.2
Baeten, D.L.3
-
51
-
-
77951091571
-
Circulating Th17, Th22, and Th1 cells are increased in psoriasis
-
Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A,. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-1383.
-
(2010)
J Invest Dermatol
, vol.130
, pp. 1373-1383
-
-
Kagami, S.1
Rizzo, H.L.2
Lee, J.J.3
Koguchi, Y.4
Blauvelt, A.5
-
52
-
-
84925209356
-
IL-17A production in human psoriatic blood and lesions by CD146+ T cells
-
Mehta NN, Dagur PK, Rose SM, et al,. IL-17A production in human psoriatic blood and lesions by CD146+ T cells. J Invest Dermatol 2015; 135: 311-314.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 311-314
-
-
Mehta, N.N.1
Dagur, P.K.2
Rose, S.M.3
-
53
-
-
79951743212
-
Functional specialization of interleukin-17 family members
-
Iwakura Y, Ishigame H, Saijo S, Nakae S,. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-162.
-
(2011)
Immunity
, vol.34
, pp. 149-162
-
-
Iwakura, Y.1
Ishigame, H.2
Saijo, S.3
Nakae, S.4
-
54
-
-
84906311286
-
IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms
-
Ha HL, Wang H, Pisitkun P, et al,. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA 2014; 111: E3422-E3431.
-
(2014)
Proc Natl Acad Sci USA
, vol.111
, pp. E3422-E3431
-
-
Ha, H.L.1
Wang, H.2
Pisitkun, P.3
-
55
-
-
84931566876
-
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
-
Reich K, Papp KA, Matheson RT, et al,. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol 2015; 24: 529-535.
-
(2015)
Exp Dermatol
, vol.24
, pp. 529-535
-
-
Reich, K.1
Papp, K.A.2
Matheson, R.T.3
-
56
-
-
84925381286
-
IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions
-
D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, et al,. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 2015; 135: 1025-1032.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 1025-1032
-
-
D'Erme, A.M.1
Wilsmann-Theis, D.2
Wagenpfeil, J.3
-
57
-
-
84925650548
-
IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease
-
Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S,. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm Bowel Dis 2014; 20: 1891-1901.
-
(2014)
Inflamm Bowel Dis
, vol.20
, pp. 1891-1901
-
-
Friedrich, M.1
Tillack, C.2
Wollenberg, A.3
Schauber, J.4
Brand, S.5
-
58
-
-
84868613788
-
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
-
Tortola L, Rosenwald E, Abel B, et al,. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012; 122: 3965-3976.
-
(2012)
J Clin Invest
, vol.122
, pp. 3965-3976
-
-
Tortola, L.1
Rosenwald, E.2
Abel, B.3
-
60
-
-
84922352134
-
The translational revolution and use of biologics in patients with inflammatory skin diseases
-
Noda S, Krueger JG, Guttman-Yassky E,. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015; 135: 324-336.
-
(2015)
J Allergy Clin Immunol
, vol.135
, pp. 324-336
-
-
Noda, S.1
Krueger, J.G.2
Guttman-Yassky, E.3
-
61
-
-
84885180849
-
Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis
-
Shimauchi T, Hirakawa S, Suzuki T, et al,. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol 2013; 40: 805-812.
-
(2013)
J Dermatol
, vol.40
, pp. 805-812
-
-
Shimauchi, T.1
Hirakawa, S.2
Suzuki, T.3
-
62
-
-
84911936567
-
Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points
-
Puig L, López A, Vilarrasa E, García I,. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2014; 28: 1633-1653.
-
(2014)
J Eur Acad Dermatol Venereol
, vol.28
, pp. 1633-1653
-
-
Puig, L.1
López, A.2
Vilarrasa, E.3
García, I.4
-
63
-
-
84904545875
-
Secukinumab in plaque psoriasis-results of two phase 3 trials
-
Langley RG, Elewski BE, Lebwohl M, et al,. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
-
(2014)
N Engl J Med
, vol.371
, pp. 326-338
-
-
Langley, R.G.1
Elewski, B.E.2
Lebwohl, M.3
-
64
-
-
84859017988
-
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
-
Papp KA, Leonardi C, Menter A, et al,. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189.
-
(2012)
N Engl J Med
, vol.366
, pp. 1181-1189
-
-
Papp, K.A.1
Leonardi, C.2
Menter, A.3
-
65
-
-
84938992082
-
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials
-
S0140-6736(15)60125-8
-
Griffiths CE, Reich K, Lebwohl M, et al,. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; pii: S0140-6736(15)60125-8.
-
(2015)
Lancet
-
-
Griffiths, C.E.1
Reich, K.2
Lebwohl, M.3
-
66
-
-
80051726086
-
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
-
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA,. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-668.
-
(2011)
Br J Dermatol
, vol.165
, pp. 661-668
-
-
Strober, B.E.1
Crowley, J.J.2
Yamauchi, P.S.3
Olds, M.4
Williams, D.A.5
-
67
-
-
84945443119
-
Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial
-
Papp K, Thaçi D, Reich K, et al,. Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial. Br J Dermatol 2015; doi: 10.1111/bjd.13932.
-
(2015)
Br J Dermatol
-
-
Papp, K.1
Thaçi, D.2
Reich, K.3
-
68
-
-
84936763292
-
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
-
Gordon KB, Duffin KC, Bissonnette R, et al,. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med 2015; 373 (2): 136-144.
-
(2015)
N Engl J Med
, vol.373
, Issue.2
, pp. 136-144
-
-
Gordon, K.B.1
Duffin, K.C.2
Bissonnette, R.3
-
69
-
-
84915805860
-
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
-
Ohtsuki M, Morita A, Abe M, et al,. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41: 1039-1046.
-
(2014)
J Dermatol
, vol.41
, pp. 1039-1046
-
-
Ohtsuki, M.1
Morita, A.2
Abe, M.3
-
70
-
-
84876003723
-
Long-term efficacy of psoriasis vulgaris treatments: Analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010
-
Akasaka E, Mabuchi T, Manabe Y, et al,. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. J Dermatol 2013; 40: 238-243.
-
(2013)
J Dermatol
, vol.40
, pp. 238-243
-
-
Akasaka, E.1
Mabuchi, T.2
Manabe, Y.3
-
71
-
-
84903814736
-
Remission period in psoriasis after multiple cycles of narrowband ultraviolet B phototherapy
-
Ryu HH, Choe YS, Jo S, Youn JI, Jo SJ,. Remission period in psoriasis after multiple cycles of narrowband ultraviolet B phototherapy. J Dermatol 2014; 41: 622-627.
-
(2014)
J Dermatol
, vol.41
, pp. 622-627
-
-
Ryu, H.H.1
Choe, Y.S.2
Jo, S.3
Youn, J.I.4
Jo, S.J.5
-
72
-
-
84899998616
-
Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy
-
Ito T, Furukawa F, Iwatsuki K, et al,. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy. J Dermatol 2014; 41: 377-381.
-
(2014)
J Dermatol
, vol.41
, pp. 377-381
-
-
Ito, T.1
Furukawa, F.2
Iwatsuki, K.3
-
73
-
-
84878584345
-
Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week
-
Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol 2013; 40: 424-427.
-
(2013)
J Dermatol
, vol.40
, pp. 424-427
-
-
Takahashi, H.1
Tsuji, H.2
Ishida-Yamamoto, A.3
Iizuka, H.4
-
74
-
-
84913553366
-
Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis
-
Hayashi M, Umezawa Y, Fukuchi O, et al,. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol 2014; 41: 974-980.
-
(2014)
J Dermatol
, vol.41
, pp. 974-980
-
-
Hayashi, M.1
Umezawa, Y.2
Fukuchi, O.3
-
75
-
-
84934444687
-
Ustekinumab treatment in patients with psoriasis undergoing hemodialysis
-
Umezawa Y, Hayashi M, Kikuchi S, et al,. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol 2015; 42: 731-744.
-
(2015)
J Dermatol
, vol.42
, pp. 731-744
-
-
Umezawa, Y.1
Hayashi, M.2
Kikuchi, S.3
-
76
-
-
84934444267
-
Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure
-
Kusakari Y, Yamasaki K, Takahashi T, et al,. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J Dermatol 2015; 42: 727-730.
-
(2015)
J Dermatol
, vol.42
, pp. 727-730
-
-
Kusakari, Y.1
Yamasaki, K.2
Takahashi, T.3
-
77
-
-
84947024119
-
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
-
Warren RB, Smith CH, Yiu ZZ, et al,. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; doi: 10.1038/jid.2015.208.
-
(2015)
J Invest Dermatol
-
-
Warren, R.B.1
Smith, C.H.2
Yiu, Z.Z.3
-
78
-
-
84890441414
-
Drug survival rates in patients with psoriasis after treatment with biologics
-
Umezawa Y, Nobeyama Y, Hayashi M, et al,. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 2013; 40: 1008-1013.
-
(2013)
J Dermatol
, vol.40
, pp. 1008-1013
-
-
Umezawa, Y.1
Nobeyama, Y.2
Hayashi, M.3
-
79
-
-
84925230736
-
Immunogenicity of biotherapy used in psoriasis: The science behind the scenes
-
Jullien D, Prinz JC, Nestle FO,. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol 2015; 135: 31-38.
-
(2015)
J Invest Dermatol
, vol.135
, pp. 31-38
-
-
Jullien, D.1
Prinz, J.C.2
Nestle, F.O.3
-
80
-
-
84877781173
-
Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: Report of two cases
-
Matsumoto Y, Maeda T, Tsuboi R, Okubo Y,. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40: 389-392.
-
(2013)
J Dermatol
, vol.40
, pp. 389-392
-
-
Matsumoto, Y.1
Maeda, T.2
Tsuboi, R.3
Okubo, Y.4
-
81
-
-
84920511919
-
Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development
-
Kawakami H, Maeda T, Abe N, et al,. Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol 2015; 42: 94-95.
-
(2015)
J Dermatol
, vol.42
, pp. 94-95
-
-
Kawakami, H.1
Maeda, T.2
Abe, N.3
-
82
-
-
84872489883
-
Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
-
Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39-42.
-
(2013)
J Dermatol
, vol.40
, pp. 39-42
-
-
Takahashi, H.1
Tsuji, H.2
Ishida-Yamamoto, A.3
Iizuka, H.4
-
83
-
-
84883516165
-
Japanese guidance for use of biologics for psoriasis (the 2013 version)
-
Ohtsuki M, Terui T, Ozawa A, et al,. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013; 40: 683-695.
-
(2013)
J Dermatol
, vol.40
, pp. 683-695
-
-
Ohtsuki, M.1
Terui, T.2
Ozawa, A.3
-
84
-
-
84878585020
-
Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis
-
Koga M, Terawaki S, Tatsukawa R, et al,. Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis. J Dermatol 2013; 40: 476-477.
-
(2013)
J Dermatol
, vol.40
, pp. 476-477
-
-
Koga, M.1
Terawaki, S.2
Tatsukawa, R.3
-
85
-
-
84895068985
-
Risk of herpes zoster in psoriatic patients undergoing biologic treatment
-
Umezawa Y, Fukuchi O, Ito T, et al,. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol 2014; 41: 168-170.
-
(2014)
J Dermatol
, vol.41
, pp. 168-170
-
-
Umezawa, Y.1
Fukuchi, O.2
Ito, T.3
-
86
-
-
84886954078
-
Generalized pustular psoriasis triggered by infliximab in two patients with Crohn's disease
-
Kato Y, Yamamoto T,. Generalized pustular psoriasis triggered by infliximab in two patients with Crohn's disease. J Dermatol 2013; 40: 932-933.
-
(2013)
J Dermatol
, vol.40
, pp. 932-933
-
-
Kato, Y.1
Yamamoto, T.2
-
87
-
-
84940732204
-
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
-
Pugliese D, Guidi L, Ferraro PM, et al,. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015; 42: 880-888.
-
(2015)
Aliment Pharmacol Ther
, vol.42
, pp. 880-888
-
-
Pugliese, D.1
Guidi, L.2
Ferraro, P.M.3
-
88
-
-
84915798381
-
Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis
-
Mabuchi T, Yamaoka H, Kawai M, Ota T, Ozawa A,. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis. J Dermatol 2014; 41: 1136-1137.
-
(2014)
J Dermatol
, vol.41
, pp. 1136-1137
-
-
Mabuchi, T.1
Yamaoka, H.2
Kawai, M.3
Ota, T.4
Ozawa, A.5
|